Ocrelizumab therapy and long-term outcomes in multiple sclerosis: clinical and MRI-efficacyand safety profile
Ocrelizumab (Ocrevus®) is a humanized anti-CD20 monoclonal antibody approved for the treatment of adults with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The article presents data on the clinical and MRI efficacy and safety profile of ocrelizumab for the lon...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2019-06-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/3036 |
| _version_ | 1797842086522781696 |
|---|---|
| author | D. L. Klabukova M. V. Davydovskaya |
| author_facet | D. L. Klabukova M. V. Davydovskaya |
| author_sort | D. L. Klabukova |
| collection | DOAJ |
| description | Ocrelizumab (Ocrevus®) is a humanized anti-CD20 monoclonal antibody approved for the treatment of adults with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The article presents data on the clinical and MRI efficacy and safety profile of ocrelizumab for the long-term use in patients with MS of various forms of the course. The authors performed the search, systematization and analysis of the pooled data of clinical studies and real clinical practice. Five-year follow-upof ocrelizumab therapy showed a compelling and clinical ly significant advantage in reducing the disease progression in patients with PPMS. After five-year ocrelizumab therapy in patients with PPMS, the study showed a reduction of the proportion of patients with disease progression and degree of brain atrophy, and more frequent achievement of the disease inactivity status (NEDA) as compared to patients with two- year delayed initiation of ocrelizumab therapy. The safety profile of the drug corresponds to the results obtained in the controlled periods of clinical trials. |
| first_indexed | 2024-04-09T16:42:06Z |
| format | Article |
| id | doaj.art-2cbc2ad8dd7c445f811d2079376c0db4 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:42:06Z |
| publishDate | 2019-06-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-2cbc2ad8dd7c445f811d2079376c0db42023-04-23T06:56:38ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902019-06-0109647110.21518/2079-701X-2019-9-64-712951Ocrelizumab therapy and long-term outcomes in multiple sclerosis: clinical and MRI-efficacyand safety profileD. L. Klabukova0M. V. Davydovskaya1State Budgetary Institution of the city of Moscow «Scientific and Practical Center for Clinical Research and Medical Technology Assessment of Moscow Healthcare Department».State Budgetary Institution of the city of Moscow «Scientific and Practical Center for Clinical Research and Medical Technology Assessment of Moscow Healthcare Department»; Federal State Budgetary Educational Institution of Higher Education Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of the Russian Federation.Ocrelizumab (Ocrevus®) is a humanized anti-CD20 monoclonal antibody approved for the treatment of adults with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The article presents data on the clinical and MRI efficacy and safety profile of ocrelizumab for the long-term use in patients with MS of various forms of the course. The authors performed the search, systematization and analysis of the pooled data of clinical studies and real clinical practice. Five-year follow-upof ocrelizumab therapy showed a compelling and clinical ly significant advantage in reducing the disease progression in patients with PPMS. After five-year ocrelizumab therapy in patients with PPMS, the study showed a reduction of the proportion of patients with disease progression and degree of brain atrophy, and more frequent achievement of the disease inactivity status (NEDA) as compared to patients with two- year delayed initiation of ocrelizumab therapy. The safety profile of the drug corresponds to the results obtained in the controlled periods of clinical trials.https://www.med-sovet.pro/jour/article/view/3036ocrelizumabmultiple sclerosisefficacysafetylong-term outcomes |
| spellingShingle | D. L. Klabukova M. V. Davydovskaya Ocrelizumab therapy and long-term outcomes in multiple sclerosis: clinical and MRI-efficacyand safety profile Медицинский совет ocrelizumab multiple sclerosis efficacy safety long-term outcomes |
| title | Ocrelizumab therapy and long-term outcomes in multiple sclerosis: clinical and MRI-efficacyand safety profile |
| title_full | Ocrelizumab therapy and long-term outcomes in multiple sclerosis: clinical and MRI-efficacyand safety profile |
| title_fullStr | Ocrelizumab therapy and long-term outcomes in multiple sclerosis: clinical and MRI-efficacyand safety profile |
| title_full_unstemmed | Ocrelizumab therapy and long-term outcomes in multiple sclerosis: clinical and MRI-efficacyand safety profile |
| title_short | Ocrelizumab therapy and long-term outcomes in multiple sclerosis: clinical and MRI-efficacyand safety profile |
| title_sort | ocrelizumab therapy and long term outcomes in multiple sclerosis clinical and mri efficacyand safety profile |
| topic | ocrelizumab multiple sclerosis efficacy safety long-term outcomes |
| url | https://www.med-sovet.pro/jour/article/view/3036 |
| work_keys_str_mv | AT dlklabukova ocrelizumabtherapyandlongtermoutcomesinmultiplesclerosisclinicalandmriefficacyandsafetyprofile AT mvdavydovskaya ocrelizumabtherapyandlongtermoutcomesinmultiplesclerosisclinicalandmriefficacyandsafetyprofile |